Third Harmonic Bio Inc. Stockholders Approve Liquidation Plan, Initiates Sale of THB335 Asset
I'm PortAI, I can summarize articles.
Third Harmonic Bio, Inc. has received stockholder approval for its liquidation plan, initiating the sale of its asset THB335, an oral wild-type KIT inhibitor. The Phase 1 trial showed an 85% reduction in serum tryptase, paving the way for a Phase 2 trial pending FDA clearance. Stockholders can expect an initial distribution of $5.30 to $5.35 per share in Q3 2025. Interested buyers should contact Chris Murphy for details.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments